Genomtec S.A. - Asset Resilience Ratio
Genomtec S.A. (GMT) has an Asset Resilience Ratio of 18.10% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GMT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Genomtec S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Genomtec S.A. assets under control.
Liquid Assets Composition Over Time
This chart breaks down Genomtec S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Genomtec S.A. carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł4.50 Million | 18.1% |
| Total Liquid Assets | zł4.50 Million | 18.10% |
Asset Resilience Insights
- Good Liquidity Position: Genomtec S.A. maintains a healthy 18.10% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Genomtec S.A. Industry Peers by Asset Resilience Ratio
Compare Genomtec S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
|
Profound Medical Corp
TO:PRN |
Medical Devices | 67.66% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
Epitomee Medical Ltd
TA:EPIT |
Medical Devices | 0.24% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
Annual Asset Resilience Ratio for Genomtec S.A. (None–None)
The table below shows the annual Asset Resilience Ratio data for Genomtec S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more